<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1003" relname="attribution">It is believed</segment>
<segment id="3" parent="1003" relname="joint">that an ideal vaccine against Leishmania spp .</segment>
<segment id="4" parent="1005" relname="span">should have epitopes</segment>
<segment id="5" parent="4" relname="elaboration">that will be recognized by APCs</segment>
<segment id="6" parent="1006" relname="joint">and will be able to trigger a T- lymphocyte effector response</segment>
<segment id="7" parent="1007" relname="span">and maintain a long-lasting immune memory ,</segment>
<segment id="8" parent="7" relname="elaboration">which would be critical for protection against the parasite .</segment>
<segment id="9" parent="1008" relname="joint">Therefore , the high-throughput search for epitopes with this potential has become one of the greatest current challenges for the rational design of vaccines .</segment>
<segment id="10" parent="1008" relname="joint">Thus , reverse vaccinology started to be used for this purpose ,</segment>
<segment id="11" parent="1011" relname="span">and one of the strategies</segment>
<segment id="12" parent="11" relname="elaboration">used is the search for immunogenic epitopes in whole Leishmania proteomes .</segment>
<segment id="13" parent="1013" relname="span">Epitope mapping in proteomes of parasites is much more complex than the mapping of epitopes in proteins</segment>
<segment id="14" parent="13" relname="elaboration">already described as immunogenic .</segment>
<segment id="15" parent="1016" relname="span">In this way , the use of the integrative approach to immunoinformatics</segment>
<segment id="16" parent="15" relname="elaboration">proposed by Brito , Guimaraes , Velloso , Correa-Oliveira , Ruiz , Reis and Resende was important</segment>
<segment id="17" parent="1016" relname="purpose">to achieve potential epitopes in this study .</segment>
<segment id="18" parent="1019" relname="circumstance">After employing the immunoinformatics methodologies ,</segment>
<segment id="19" parent="1019" relname="span">we identified MHC class I and class II ligand epitopes</segment>
<segment id="20" parent="1020" relname="span">comprising mouse and human alleles ,</segment>
<segment id="21" parent="1021" relname="span">due to the absence of predictors</segment>
<segment id="22" parent="21" relname="elaboration">comprising dog alleles .</segment>
<segment id="23" parent="1023" relname="same_unit">However ,</segment>
<segment id="24" parent="25" relname="attribution">based on some studies , we can verify</segment>
<segment id="25" parent="1024" relname="span">that there are high levels of identity between MHC alleles of dogs and those of humans and mice .</segment>
<segment id="26" parent="1026" relname="span">For example , some loci of the MHC region II of dogs have an identity with those of humans and mice around 85 % and 79 % , respectively .</segment>
<segment id="27" parent="1027" relname="span">Regarding the in vivo screening of the immunoinformatics-selected peptides in the canine model ,</segment>
<segment id="28" parent="1028" relname="span">we selected asymptomatic dogs</segment>
<segment id="29" parent="1029" relname="span">naturally infected by L. infantum</segment>
<segment id="30" parent="29" relname="elaboration">( natural reservoir ) .</segment>
<segment id="31" parent="32" relname="attribution">Several studies have shown</segment>
<segment id="32" parent="1031" relname="span">that dogs and humans with asymptomatic clinical forms have better reactivity with intra-dermal reaction than symptomatic individuals .</segment>
<segment id="33" parent="1034" relname="attribution">Similarly , Reis , et al. have already shown</segment>
<segment id="34" parent="1034" relname="span">that asymptomatic dogs have a profile of circulating lymphocytes in the peripheral blood</segment>
<segment id="35" parent="34" relname="elaboration">capable of conferring a degree of resistance to the disease .</segment>
<segment id="36" parent="37" relname="circumstance">When we performed the in vitro screening ,</segment>
<segment id="37" parent="1036" relname="span">the purpose was to identify potential epitopes in a huge number of peptides .</segment>
<segment id="38" parent="1038" relname="span">For this , we focused on the main biomarkers of protection ,</segment>
<segment id="39" parent="1040" relname="preparation">namely :</segment>
<segment id="40" parent="1040" relname="span">lymphocyte proliferation after stimulation with L. infantum and IFN-γ production by subpopulations of T-lymphocytes</segment>
<segment id="41" parent="40" relname="elaboration">( CD4+ and CD8+ ) .</segment>
<segment id="42" parent="1042" relname="span">Currently , some markers</segment>
<segment id="43" parent="42" relname="elaboration">related to protection have been studied , such as proinflammatory cytokines , production of immunoglobulins of IgG1 and IgG2 subtypes , and responsive CD4+ and CD8+ T-cells .</segment>
<segment id="44" parent="1046" relname="span">The biomarkers</segment>
<segment id="45" parent="44" relname="elaboration">that we chose</segment>
<segment id="46" parent="1045" relname="same_unit">are essential</segment>
<segment id="47" parent="1047" relname="joint">to determine resistance or susceptibility to visceral leishmaniasis</segment>
<segment id="48" parent="1047" relname="joint">and they are widely demonstrated in the literature .</segment>
<segment id="49" parent="50" relname="attribution">Our data support</segment>
<segment id="50" parent="1049" relname="span">that some peptides were able to induce lymphoproliferation and the production of IFN-γ by T-cells in vitro .</segment>
<segment id="51" parent="1051" relname="span">In this regard , in many studies</segment>
<segment id="52" parent="1053" relname="circumstance">reporting the use of murine model and PBMC from patients with leishmaniasis ,</segment>
<segment id="53" parent="1053" relname="span">the main biomarker</segment>
<segment id="54" parent="1054" relname="span">analyzed was IFN-γ</segment>
<segment id="55" parent="54" relname="elaboration">produced after stimuli with different peptides .</segment>
<segment id="56" parent="1057" relname="span">After the in vitro screening , the reverse antigen screening</segment>
<segment id="57" parent="56" relname="restatement">( RAS )</segment>
<segment id="58" parent="1058" relname="span">was used , a robust methodology</segment>
<segment id="59" parent="1059" relname="span">that allows the selection of promising targets for the development of vaccines</segment>
<segment id="60" parent="59" relname="elaboration">intended to trigger a strong cellular response .</segment>
<segment id="61" parent="1062" relname="attribution">Our findings demonstrate</segment>
<segment id="62" parent="1062" relname="span">that an immunoinformatic approach increases the chance</segment>
<segment id="63" parent="1064" relname="span">of finding peptides molecules</segment>
<segment id="64" parent="63" relname="restatement">( epitopes )</segment>
<segment id="65" parent="1064" relname="elaboration">which can trigger a cellular response in a naturally and asymptomatic infected model .</segment>
<segment id="66" parent="1067" relname="span">The fact</segment>
<segment id="67" parent="1068" relname="span">that an antigen generates a cellular response</segment>
<segment id="68" parent="67" relname="elaboration">classified as type IV or late hypersensitivity implies</segment>
<segment id="69" parent="1069" relname="joint">that this antigen may be able to generate immune memory</segment>
<segment id="70" parent="1070" relname="span">and trigger a response</segment>
<segment id="71" parent="70" relname="elaboration">characterized by important cytokines , such as IFN-γ and TNF-α .</segment>
<segment id="72" parent="1073" relname="circumstance">When we analyzed the epitope conservancy of these peptides among the proteome of other Leishmania species ,</segment>
<segment id="73" parent="74" relname="attribution">it was observed</segment>
<segment id="74" parent="1073" relname="span">that peptide PEP17 demonstrated to be the most conserved epitope among various viscerotropic and dermatotropic Leishmania species .</segment>
<segment id="75" parent="1076" relname="span">Immunogenic peptides</segment>
<segment id="76" parent="75" relname="elaboration">that show a high degree of conservancy with other parasites</segment>
<segment id="77" parent="1077" relname="span">may be related to a better protection</segment>
<segment id="78" parent="77" relname="circumstance">when compared to those not conserved .</segment>
<segment id="79" parent="1074" relname="span">In this way , peptides 17 , 30 , 33 , and 34 may be considered promising epitopes for the design of vaccines against VL .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1008" relname="background"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="multinuc" parent="1003" relname="joint"/>
<group id="1005" type="span" parent="1004" relname="joint"/>
<group id="1006" type="multinuc" parent="1004" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="joint"/>
<group id="1008" type="multinuc" parent="1001" relname="span"/>
<group id="1011" type="span" parent="1008" relname="joint"/>
<group id="1013" type="span" parent="1008" relname="joint"/>
<group id="1014" type="multinuc" parent="1008" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="sequence"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1017" type="multinuc" parent="1014" relname="sequence"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="span" parent="1018" relname="span"/>
<group id="1020" type="span" parent="19" relname="elaboration"/>
<group id="1021" type="span" parent="20" relname="cause"/>
<group id="1023" type="multinuc" parent="1017" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="same_unit"/>
<group id="1026" type="span" parent="1017" relname="joint"/>
<group id="1027" type="span" parent="26" relname="elaboration"/>
<group id="1028" type="span" parent="27" relname="elaboration"/>
<group id="1029" type="span" parent="28" relname="elaboration"/>
<group id="1031" type="span" parent="1017" relname="joint"/>
<group id="1033" type="span" parent="1017" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="span"/>
<group id="1035" type="span" parent="1017" relname="joint"/>
<group id="1036" type="span" parent="1035" relname="span"/>
<group id="1037" type="multinuc" parent="1036" relname="purpose"/>
<group id="1038" type="span" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="38" relname="elaboration"/>
<group id="1040" type="span" parent="1039" relname="span"/>
<group id="1041" type="multinuc" parent="1037" relname="joint"/>
<group id="1042" type="span" parent="1041" relname="joint"/>
<group id="1043" type="multinuc" parent="1041" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="multinuc" parent="1044" relname="span"/>
<group id="1046" type="span" parent="1045" relname="same_unit"/>
<group id="1047" type="multinuc" parent="1045" relname="purpose"/>
<group id="1048" type="span" parent="1043" relname="joint"/>
<group id="1049" type="span" parent="1050" relname="preparation"/>
<group id="1050" type="multinuc" parent="1048" relname="span"/>
<group id="1051" type="span" parent="1050" relname="sequence"/>
<group id="1052" type="span" parent="51" relname="elaboration"/>
<group id="1053" type="span" parent="1052" relname="span"/>
<group id="1054" type="span" parent="53" relname="elaboration"/>
<group id="1055" type="multinuc" parent="1050" relname="sequence"/>
<group id="1056" type="multinuc" parent="1055" relname="sequence"/>
<group id="1057" type="span" parent="1056" relname="same_unit"/>
<group id="1058" type="span" parent="1056" relname="same_unit"/>
<group id="1059" type="span" parent="58" relname="elaboration"/>
<group id="1060" type="multinuc" parent="1055" relname="sequence"/>
<group id="1061" type="span" parent="1060" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="span"/>
<group id="1063" type="span" parent="62" relname="elaboration"/>
<group id="1064" type="span" parent="1063" relname="span"/>
<group id="1065" type="span" parent="1060" relname="joint"/>
<group id="1066" type="span" parent="1065" relname="span"/>
<group id="1067" type="span" parent="1069" relname="attribution"/>
<group id="1068" type="span" parent="66" relname="elaboration"/>
<group id="1069" type="multinuc" parent="1066" relname="span"/>
<group id="1070" type="span" parent="1069" relname="joint"/>
<group id="1071" type="multinuc" parent="1066" relname="elaboration"/>
<group id="1072" type="span" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1072" relname="span"/>
<group id="1074" type="span" parent="1071" relname="joint"/>
<group id="1075" type="multinuc" parent="79" relname="background"/>
<group id="1076" type="span" parent="1075" relname="same_unit"/>
<group id="1077" type="span" parent="1075" relname="same_unit"/>
	</body>
</rst>
